Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
RESEARCH TOOLSreports
Supernus Pharmaceuticals (SUPN) Stock Price & Analysis
449 Followers
SUPN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.99 - $42.09
Previous Close$26.78
Volume369.76K
Average Volume (3M)440.61K
Market Cap
$1.52B
Enterprise Value$1.35B
Total Cash (Recent Filing)$200.19M
Total Debt (Recent Filing)$33.84M
Price to Earnings (P/E)69.0
Beta0.57
Next Earnings
Feb 27, 2024EPS Estimate
$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding54,632,847
10 Day Avg. Volume263,072
30 Day Avg. Volume440,609
Standard Deviation0.11
R-Squared0.31
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)9.85
Price to Sales (P/S)2.19
Price to Cash Flow (P/CF)10.60
P/FCF Ratio10.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda11.89
Forecast
1Y Price Target
$43.00Price Target Upside57.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Supernus Pharmaceuticals News
Press ReleasesSupernus Announces Third Quarter 2023 Financial Results
SUPN FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest stock price was $21.99 and its highest was $42.09 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Currently, no data Available
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Feb 27, 2024 which is in 81 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Nov 08, 2023. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.295.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is $0.41.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 54,632,847 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of -$0.29 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went up 11.139%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Third Avenue Management LLC. It holds Supernus Pharmaceuticals’s shares valued at 3M.
---
Supernus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (57.68% Upside)
$43.00 (57.68% Upside)
Blogger Sentiment
Bullish
SUPN Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 52.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $290.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.77%
12-Months-Change
Fundamentals
Return on Equity
2.90%
Trailing 12-Months
Asset Growth
-24.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
Top 5 ETFs holding SUPN
Vanguard Total Stock Market ETF
$38.98M
Vanguard Health Care ETF
$4.46M
Vanguard Russell 3000 ETF
$74.46K
SPDR S&P 1500 Value Tilt ETF
$11.61K
Invesco S&P US Total Market ESG Tilt Index ETF Trust Units -CAD Hedged-
$37.67
Up to five ETFs with an Outperform Smart Score that hold SUPN. The ETFs are listed according to market value of SUPN within the ETF
---